局部晚期不可手术食管癌同步放化疗联合尼妥珠单抗的初步临床分析  

Preliminary clinical analysis of concurrent chemoradiotherapy combined with nituzumab for inoperable locally advanced esophageal cancer

作　　者：曾程 杨丹 杜荣旭 姜蕾蕾 董昕 李东明[1] 余荣[1] 于会明 石安辉[1] Zeng Cheng;Yang Dan;Du Rongxu;Jiang Leilei;Dong Xin;Li Dongming;Yu Rong;Yu Huiming;Shi Anhui(Department of Radiation Oncology,Peking University Cancer Hospital&Institute,Key Laboratory of Carcinogenesis and Translational Research,Peking University College of Clinical Oncology,Beijing 100142,China;Department of Oncology,General Hospital of Central Theater Command of Chinese People's Liberation Army,Wuhan 430070,China)

机构地区：[1]北京大学临床肿瘤学院恶性肿瘤发病机制及转化研究教育部重点实验室,北京大学肿瘤医院暨北京市肿瘤防治研究所放疗科,100142 [2]中国人民解放军中部战区总医院肿瘤科,武汉430070

出　　处：《中华放射肿瘤学杂志》2021年第4期353-356,共4页Chinese Journal of Radiation Oncology

基　　金：北京市卫生健康委员会适宜技术推广项目(BHTPP202026)。

摘　　要：目的探讨局部晚期食管癌同步放化疗联合尼妥珠单抗治疗的不良反应及疗效。方法回顾性分析北京大学肿瘤医院2015—2020年间使用同步放化疗联合尼妥珠单抗治疗的30例患者资料,采用Kaplan-Meier法生存分析。结果中位随访时间22.5个月,总客观有效率为93%。1、2、3年总生存率分别为83%、57%、41%,无进展生存率分别为75%、47%、32%,无局部区域复发率分别为83%、53%、37%,无远处转移生存率分别为75%、51%、36%。≥3级血液学不良反应发生率为32%,3级放射性食管炎发生率为16%。结论局部晚期食管癌同步放化疗联合尼妥珠单抗初步结果显示安全有效。Objective The standard treatment for inoperable locally advanced esophageal cancer is concurrent chemoradiotherapy,but the survival was not satisfied.Nituzumab is a humanized IgG monoclonal antibody against EGFR.The purpose of this study is to investigate the toxicity and efficacy of concurrent chemoradiotherapy combined with nituzumab for locally advanced esophageal cancer.Methods We retrospectively reviewed the clinical data of locally advanced esophageal cancer who were treated with concurrent chemoradiotherapy combined with nituzumab in Peking University Cancer Hospital from June 2015 to June 2020.Kaplan-Meier method was used for analysis.Results Thirty Patients were enrolled this study.After a median follow-up of 22.5 months,The objective response rate was 93%.The 1-year,2-year,3-year overall survival rates were 83%,57%and 41%,with the progression-free survival rates 75%,47%and 32%,with the local-recurrence free survival rates 83%,53%and 37%,with the metastasis-free survival rates 75%,51%and 36%,respectively.The incidence of grade≥3 hematological toxicity was 32%.There were 16%patients experiencing grade≥3 esophagitis.Conclusion The preliminary result of concurrent chemoradiotherapy combined with nituzumab is effective and safe for patients with locally advanced esophageal cancer.

关 键 词：食管肿瘤/同步放化疗法 食管肿瘤/靶向疗法 治疗结果 

分 类 号：R735.1[医药卫生—肿瘤]